BACKGROUND: High-level evidence is lacking to guide treatment decisions about postmastectomy radiation therapy (PMRT) in patients who have breast cancer with 1 to 3 positive lymph nodes who receive contemporary systemic therapies, leading to potential variations in PMRT delivery. The objective of this study was to examine nationwide trends in PMRT use in this group. METHODS: The National Cancer Data Base (NCDB) was used to identify 93,372 women who had T1-T2N1 breast cancer diagnosed between 2003 and 2012. Patients who received neoadjuvant chemotherapy or radiation therapy (RT) and those who had bilateral breast cancers were excluded. Time trends were evaluated using the Cochrane-Armitage test and correlated the receipt of PMRT with various patient demographic, facility, clinicopathologic, and treatment variables using multivariable logistic regression. A second analysis was performed for patients who were diagnosed during 2010 and included radiation oncologist density as an additional covariate. P values < .0001 were considered statistically significant. RESULTS: Overall, 22.5% of the study population received PMRT, representing an increase from 19.1% in 2003 to 30.3% in 2012. Factors associated with greater PMRT use included younger age, lower Charlson-Deyo comorbidity scores, shorter distance to the treating facility, treatment at a comprehensive cancer program, facility location in the New England Census division, and higher density of radiation oncologists. Increased PMRT use was associated with later year of diagnosis, receipt of chemotherapy, receipt of hormone therapy, higher grade disease, larger tumor size, greater numbers of positive lymph nodes, positive margins, and absence of immediate breast reconstruction (all P <.0001). CONCLUSIONS: The receipt of PMRT by patients with breast cancer who have 1 to 3 positive lymph nodes has increased over time, with wide variability in practice patterns in the United States. Cancer 2018;124:482-90.
INTRODUCTION
The value of postmastectomy radiation therapy (PMRT) in patients who have breast cancer with 1 to 3 positive lymph nodes has been a longstanding subject of debate. [1] [2] [3] Recent National Comprehensive Cancer Network guidelines recommend that PMRT be "strongly considered" in this group of patients, with the inclusion of regional lymph node irradiation. 4 In 2014, an update of the Early Breast Cancer Trialists' Collaborative Group meta-analysis demonstrated improved breast cancer mortality with the addition of PMRT in these patients. The reduction in overall recurrence with PMRT was observed not only in patients with 2 or 3 positive lymph nodes but also in those with only 1 positive lymph node. 5 Trials that were included in this meta-analysis were conducted in the 1970s through the 1990s and have been criticized for antiquated treatment regimens. In the modern era, the enhanced use of systemic therapies, improvements in surgical resection, and advancements in radiotherapy techniques have resulted in lower locoregional recurrence rates in patients with 1 to 3 positive lymph nodes, thereby limiting the applicability of these findings to current practice. [6] [7] [8] Two recently published randomized trials, European Organization for Research and Treatment of Cancer (EORTC) trial 22922 and National Cancer Institute of Canada (NCIC) trial MA.20, demonstrated that regional lymph node irradiation (RNI) improved disease-free survival but did not impact overall survival in the setting of breast cancer with 1 to 3 positive lymph nodes. 9, 10 Twenty-four percent of patients in the EORTC trial and none in the NCIC study included patients who underwent mastectomy. Nevertheless, results from these trials have been extrapolated to women who have undergone mastectomy, raising the question of whether PMRT is beneficial in all patients who have breast cancer with 1 to 3 positive lymph nodes. In a planned subgroup analysis of the MA.20 trial, estrogen receptor (ER)-positive patients appeared to have a lesser benefit from RNI relative to ER-negative patients, raising the question of whether all biologic subtypes derive similar benefits from RT.
Current PMRT practice patterns in the United States are not well characterized. Despite the randomized trial evidence in support of PMRT, large singleinstitution series have demonstrated low rates of locoregional recurrence in low-risk subsets of patients with 1 to 3 positive lymph nodes, ranging from 2% to 5% at 5 years. 6, 8 According to a recent analysis of outcomes in patients with ER-positive breast cancer who underwent mastectomy without PMRT for 1 to 3 positive lymph nodes in National Surgical Adjuvant Breast and Bowel Project trial NSABP B-28, the locoregional recurrence rate was only 6% in the subset with high Oncotype Dx (Genomic Health, Inc, Redwood City, CA) recurrence scores, and was even lower for subsets with lower recurrence scores. 11 These data suggest that biologic factors may help to identify women who will derive a greater benefit from PMRT than others. However, a lack of consistency in identifying these subsets in the era of modern surgical and systemic therapies has likely resulted in highly variable treatment patterns across the United States. Reports from national and state cancer registries have demonstrated that PMRT rates vary from 21% to 36% in these patients. [12] [13] [14] Recognizing that trends in PMRT use may have fluctuated widely over the past decade, the current study was undertaken to identify patterns and predictors of PMRT use in the United States for patients who have breast cancer with 1 to 3 positive lymph nodes using the National Cancer Data Base (NCDB).
MATERIALS AND METHODS

Data Source
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society and captures 70% of all newly diagnosed malignancies annually in the United States. NCDB registry data from 2003 to 2012 were used to examine receipt of PMRT by patients with American Joint Committee on Cancer (AJCC) stage IIA or IIB breast cancer who had 1 to 3 positive lymph nodes. The data used in this study were derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used or the conclusions drawn from these data by the investigators. This study was granted human research exemption from the Memorial Sloan Kettering Cancer Center institutional review board. Data on patient demographics, comorbidity scores, insurance type, income, treatment facility, immediate breast reconstruction (IBR), and disease variables were collected.
Study Population
The study population was comprised of patients with pathologic AJCC stage IIA or IIB (AJCC Cancer Staging Manual, sixth or seventh edition) invasive breast cancer diagnosed between 2003 and 2012 who underwent mastectomy with 1 to 3 pathologically positive lymph nodes. Patients with clinical or pathologic evidence of distant metastatic disease, those with bilateral breast cancer, and those who received neoadjuvant or intraoperative therapies were excluded. Patients who did not receive any treatment at the reporting facility were excluded.
Postmastectomy Radiation
PMRT was defined as receipt of 45 to 65 gray (Gy) of external-beam RT to the chest wall with or without regional lymph nodes. PMRT was required to commence within 365 days of diagnosis to include patients who received adjuvant chemotherapy and to exclude patients in whom PMRT was significantly delayed or delivered with palliative intent. Specific lymph node target volumes (axillary vs supraclavicular vs internal mammary lymph nodes) were not specified in the NCDB.
Axillary Treatment
The number of lymph nodes removed was specified in the NCDB. However, the axillary surgery type (sentinel lymph node biopsy vs axillary dissection) was not defined. Details regarding the size of tumor metastasis in the regional lymph nodes or the presence or absence of extranodal extension also were not available.
Statistical Analysis
Patient demographic, facility, clinicopathologic, and treatment details were compared between patients who did and did not receive PMRT using chi-square tests. The Cochran-Armitage trend test was used to analyze patterns in PMRT use over the study years. Multivariable logistic regression was performed to identify factors associated with PMRT receipt for the whole cohort. A second multivariable analysis was performed for patients who were diagnosed during the year 2010 to evaluate the impact of radiation oncologist density on patient treatment. This analysis included radiation oncologists per 100,000 residents by US Census division. Radiation oncologist densities were divided into 4 categories: > 1.79, 1.59 to 1.79, 1.39 to 1.59, and <1.39 radiation oncologists per 100,000 residents. In this model, the relation between facility location by US Census division and radiation oncologist density was linearly correlated, and facility location was excluded from the multivariate model. After setting all other covariates in the model at the population mean, the adjusted probability of receiving PMRT by radiation oncologist density was estimated. Given the large sample sizes analyzed, P values < .0001 were considered statistically significant. SAS version 9.3 (SAS Institute, Cary, NC) was used for the statistical analyses.
RESULTS
In total, 92,372 patients diagnosed with breast cancer between 2003 and 2012 who underwent mastectomy and had pathologic T1-T2 primary tumors and 1 to 3 positive lymph nodes were identified. The majority of patients were white (84.0%) and had Charlson-Deyo comorbidity scores from 0 to 1 (96.9%). Among those who received PMRT, 34% had radiation administered to the chest wall only, and 66.0% had radiation administered to the chest wall and regional lymph nodes. The median PMRT dose was 55 Gy (range, 45-65 Gy). Table 1 provides baseline characteristics of the PMRT and no PMRT groups. Table 2 lists the predictors of PMRT receipt on multivariable analysis for all patients. Older age, farther distance from the treatment center, higher Charlson-Deyo comorbidity score, and IBR were associated with decreased receipt of PMRT. Patients who lived in the New England Census division, received treatment at a comprehensive cancer program, or were diagnosed in the PMRT
later years of the study period were more likely to receive PMRT. Receipt of chemotherapy or hormone therapy, higher grade disease, higher pathologic T-classification, positive surgical margins, and greater number of positive lymph nodes all were associated with increased receipt of PMRT. In another multivariable model for patients diagnosed in 2010 that included radiation oncologist density as a covariate, similar predictors of PMRT receipt were identified, with some notable differences (Table 3) . Charlson-Deyo comorbidity score and tumor grade were no longer significantly associated with PMRT receipt. Patients who lived in a US Census division with a lower density of radiation oncologists were significantly less likely to receive PMRT. The adjusted predicted probability of receiving PMRT for patients who lived in New England, which had the highest density of radiation oncologists, was 33.7%, compared with 19.4% for patients living in the US Census divisions with the lower densities of radiation oncologists (West South Central, Mountain, and East South Central) ( Table 4 and Fig. 2 ).
DISCUSSION
In this study using a large population-based database, we have demonstrated that the receipt of PMRT increased in women with T1-T2 breast cancer who had 1 to 3 pathologically positive lymph nodes over the study period. Multiple predictors of PMRT receipt were identified in our study. The effect of some of these factors on locoregional recurrence, such as an increasing number of positive lymph nodes and larger primary tumors, have been well documented in registry-based and singleinstitution reports. 6, 8, 13 PMRT was received less frequently by patients who underwent IBR. This likely reflects the reluctance of clinicians and patients to pursue PMRT because of the increased risk of reconstruction complications. 15 The limitations of the NCDB make it difficult to ascertain the important reasons for these observed differences in PMRT use based on receipt of reconstruction. The role of IBR in the use of PMRT has been explored previously using the NCDB. Recent data demonstrate that rates of PMRT in this group of reconstructed patients increased from 13% in 2004 to 33% in 2013. 16 Conversely, a Surveillance, Epidemiology, and End Results study indicated that the number of women who require PMRT and opt for IBR has increased over time between 2000 and 2010. 17 Taken together, these data suggesting that the use of PMRT and IBR are not mutually exclusive, although it is difficult to ascertain whether the indication for PMRT affects IBR or vice versa.
An important observation of our study was that PMRT was used more frequently in regions populated by a high density of radiation oncologists. The difference in the adjusted predicted probability of PMRT receipt between the lowest and highest density areas of radiation oncologists was 14.3%. These results are analogous to other large, population-based series in which the density of other specialists correlated with increased use of that particular treatment modality. For example, Jagsi et al observed that patients with breast cancer who resided in an area with higher plastic surgeon density were more likely to undergo postmastectomy reconstruction. 18 These data highlight the extent of treatment bias that may exist in regions with greater accessibility to radiation oncologists and the need for evidence-based treatment guidelines to guide PMRT decisions in the setting of breast cancer with 1 to 3 positive lymph nodes.
Our findings corroborate results from a combined analysis of patients who had breast cancer with 1 to 3 positive lymph nodes from the Surveillance, Epidemiology, and End Results program and the NCDB who underwent mastectomy between 1998 and 2008, in which the reported rate of PMRT use was similar (21.5%) to that reported in our current study (22.5%). 12 However, in that analysis, the dose range for PMRT was not specified. In an effort to minimize the potential for miscategorization of patients who received radiation with palliative intent, our study more rigorously defined PMRT as receipt of doses typically used in the adjuvant setting and included patients who received PMRT within 365 days after surgery.
An unquantifiable factor that may have contributed to the increasing use of PMRT during the latter period of the study was the effect of the NCIC MA.20 and EORTC 22922 trials, which examined the role of RNI in patients who had breast cancer with 1 to 3 positive lymph nodes. The percentages of women with 1 to 3 positive lymph nodes in the MA.20 and EORTC 22922 trials were 90% and 43%, respectively. The preliminary findings from those trials suggesting that RNI improved disease-free survival and overall survival, respectively, were presented in abstract form in 2010 and 2011. 19, 20 The majority of patients included in these trials underwent breastconserving therapy (100% in MA.20; 76% in EORTC 22922), however, these results are often extrapolated to women who undergo mastectomy. After publication of these results in 2011, the findings may have encouraged more radiation oncologists to pursue PMRT for women who had T1-T2 primary tumors with 1 to 3 positive lymph nodes. Subsequent peer-reviewed publication of these trials demonstrated a small but statistically significant benefit of RNI in patients with few positive lymph nodes. 9, 10 Furthermore, a prespecified subset analysis of ER-negative patients in NCIC MA.20 demonstrated a statistically significant increase in disease-free survival with the addition of RNI (P 5 .04), suggesting that select biologic subgroups may derive a greater benefit from RNI. Although locoregional recurrence was not reported as an endpoint in either of these trials, the improvements in disease-free survival outcomes with RNI reported in both the MA.20 and EORTC 22922 trials were clinically meaningful, particularly in light of more effective systemic therapies to treat both local and distant disease in patients with breast cancer today. 5, 21, 22 Future analyses of large population-based databases like the NCDB, which captures trends over periods after 2015, will provide additional insight into the impact of these trial results on clinical practice.
The current study has limitations because of incomplete data in the NCDB on hormone receptor status as well as human epidermal growth factor receptor 2 (HER2) status, which was not collected in the NCDB until 2010. In addition, details regarding chemotherapy regimens received, use of targeted therapies, and radiation lymph node volumes were not available. Furthermore, information regarding axillary surgery, such as volume of disease within the lymph nodes, use of sentinel lymph node biopsy, and extent of lymph node dissection, also was unavailable, limiting the ability to assess how axillary surgery type may have impacted the receipt of PMRT. Finally, the NCDB does not include data on locoregional recurrence and disease-free survival, which are critical to framing discussions about the benefits of PMRT in patients with breast cancer. In recent years, the availability of multigene panel testing has provided a biologically based rationale for selecting adjuvant therapies in patients with breast cancer. There is accumulating evidence that biologic factors, including gene expression profiles in the tumor, will be able to predict the response to both adjuvant chemotherapy and radiotherapy. The Southwest Oncology Group S1007/RxPonder trial, which closed to accrual last fall, randomized women who had hormone receptor-positive, HER2-negative breast cancer with 1 to 3 positive lymph nodes and a 21-gene recurrence score 25 to receive endocrine therapy with or without adjuvant chemotherapy. 23 This biologically driven approach to defining locoregional therapies is currently the subject of a trial in development: NCIC MA.39. That trial will assess the benefit of RNI for patients who have breast cancer with 1 to 3 positive lymph nodes and are identified as low risk by genomic assay or other biomarkers. The trial will include patients who have undergone both mastectomy and breast-conserving therapy. In the Selective Use of Post Mastectomy Radiotherapy (SUPREMO) trial, which closed to accrual in 2013, the role of PMRT without the inclusion of regional lymph node areas was investigated in 1300 patients who had intermediate-risk breast cancer, defined as T1N1, T2N1, or T2N0 with grade 3 or lymphovascular invasion. 24 Forthcoming data from these trials using contemporary systemic therapy and RT regimens will provide rich opportunities to derive prognostic and predictive assays for local recurrence risk and radiosensitivity, respectively, in women who have breast cancer with 1 to 3 positive lymph node. 25 However, information obtained from these assays must be balanced against the cost effectiveness of routinely using such strategies to guide decision making in these patients.
Not surprisingly, there was a direct correlation between the number of positive lymph nodes and receipt of PMRT in our current study. On the basis of the 2014 Early Breast Cancer Trialists' Collaborative Group metaanalysis, which demonstrated that the benefits of PMRT were observed in patient subsets with 1, 2, and 3 positive lymph nodes, an increasing number of positive lymph nodes is typically viewed as a surrogate for greater disease burden, justifying the receipt of PMRT by women who have 1 to 3 positive lymph nodes. 5 As the prognostic impact of biologic factors is clarified in the aforementioned newer clinical trials, it is possible that conventional risk factors, such as the number of involved nodes, may have less impact on determining indications for PMRT in patients who have breast cancer with 1 to 3 positive lymph nodes.
In conclusion, the receipt of PMRT by patients who had breast cancer with 1 to 3 positive lymph nodes more than doubled between 2003 and 2012, with inconsistencies in practice patterns observed across the United States. The absence of high-level evidence to guide treatment decisions in this group places an immense burden on patients and the clinicians who counsel them. This evidence gap was recently confirmed by recent guidelines and recommendations from the American Society for Clinical Oncology, the American Society for Radiation Oncology, and the Society of Surgical Oncology, which acknowledged that there is insufficient evidence to either use or omit PMRT in specific subgroups of women who have breast cancer with 1 to 3 positive lymph nodes. 26 More clinical trials that prospectively address this important question in the locoregional management of these patients are urgently needed.
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